Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease.

NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy.

The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse.

The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management.

This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.

Gastric cancer remains one of the most important malignant tumors with significant geographical and regional differences in prevalence. Despite the decrease in the incidence of gastric cancer in advanced economies, this pathology still ranks fifth among patients with malignant neoplasms. As for cancer mortality rates, stomach cancer ranks third. Stomach cancer continues to be one of the most significant oncological diseases in the world, ranking fifth in terms of prevalence according to global statistics from GLOBOCAN 2022.

Modern medicine uses diagnostic technology - Next-generation sequencing (NGS), and biomarkers play an important role in the diagnosis, prognosis, and treatment of stomach cancer. These technologies provide a deep understanding of the molecular mechanisms underlying the disease and open up new possibilities for personalized therapy. NGS allows simultaneous analysis of multiple genes and detection of mutations, changes in gene expression and other genetic features. In the context of stomach cancer, next-generation sequencing allows for identification of mutations: Detection of specific mutations associated with stomach cancer can help determine prognosis and select appropriate treatment, study of the genomic profiles of patients: To identify potential targets for therapy, including immune and targeted drugs.

With the help of NGS and biomarkers, doctors can develop individualized treatment regimens for different age groups, which increases the effectiveness of therapy and reduces side effects. Biomarker analysis allows you to track the progression of cancer and identify patients with a high risk of recurrence. The study and determination of molecular genetic markers in tumor tissues, as well as the analysis of genetic and age-related factors influencing the development of gastric cancer, is an important scientific and clinical task. Solving this problem may allow us to develop a personalized approach to patient management.

This scientific paper will address the issue of the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations of various age groups in resectable gastric cancer.

Inclusion Criteria:

• Patients with histologically confirmed diagnosis of gastric cancer
• The resectable stage of the disease (I-III)
• Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
• Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
• Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)

Exclusion Criteria:

• The presence of metastases in distant organs at the time of diagnosis
• Primary-multiple tumors
• Diagnostic and palliative surgery
• Incomplete clinical data
• Pregnancy

All consecutive patients with clinically documented primary gastric cancer undergoing elective surgery with curative intent